Format

Send to

Choose Destination
BMC Gastroenterol. 2019 Apr 27;19(1):63. doi: 10.1186/s12876-019-0973-5.

Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents.

Author information

1
Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, No. 2, Yuh-Der Road, 40447, Taichung, Taiwan.
2
Graduate Institute of Biomedical Science, China Medical University, 40442, Taichung, Taiwan.
3
School of Chinese Medicine, China Medical University, 40442, Taichung, Taiwan.
4
Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, No. 2, Yuh-Der Road, 40447, Taichung, Taiwan. dadun2022@yahoo.com.tw.
5
School of Medicine, China Medical University, 40442, Taichung, Taiwan.
6
Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, No. 2, Yuh-Der Road, 40447, Taichung, Taiwan. cypeng@mail.cmuh.org.tw.
7
School of Medicine, China Medical University, 40442, Taichung, Taiwan. cypeng@mail.cmuh.org.tw.

Abstract

BACKGROUND:

Studies on temporal changes in noninvasive fibrosis indices and liver stiffness measurement (LSM) in patients with chronic hepatitis C (CHC) treated with direct-acting antiviral agents (DAAs) are limited.

METHODS:

We retrospectively enrolled consecutive patients with CHC who had received DAAs.

RESULTS:

In total, we recruited 395 consecutive patients, of which 388 (98.2%) achieved a sustained virologic response (SVR) at 12 weeks after therapy. In patients who received DAA therapy and achieved SVR 12 weeks after therapy (n = 388), the median aspartate aminotransferase/platelet ratio index (APRI) value decreased from 1.19 (0.62-2.44) at baseline to 0.50 (0.32-0.95), 0.51 (0.31-0.92), 0.48 (0.31-0.88), and 0.52 (0.33-0.92) at week 2, week 4, end of therapy, and PW12, respectively (all P < 0.001). The median FIB-4 value decreased from 2.88 (1.56-5.60) at baseline to 2.10 (1.30-3.65), 2.15 (1.30-3.65), 2.11 (1.37-3.76), and 2.22 (1.45-3.82) at week 2, week 4, end of therapy, and PW12, respectively (all P < 0.001). The median alanine aminotransferase level significantly decreased from week 2 until PW12 (all P < 0.001). The platelet count significantly increased from 2 weeks after DAA therapy initiation until PW12 (all P < 0.001); however, the magnitude of changes in the platelet count was low. In patients with paired LSMs obtained using acoustic radiation force impulse elastography at baseline and PW12 (n = 199), the median LSM decreased from 1.78 (1.25-2.30) m/s at baseline to 1.38 (1.14-1.88) m/s at PW12 (P < 0.001).

CONCLUSIONS:

Noninvasive fibrosis indices, namely APRI and FIB-4, exhibited a rapid and sustained decline from week 2 until PW12 in patients with CHC who achieved SVR to DAA therapy. The rapid decline in APRI and FIB-4 values might mainly result from improvement in necroinflammation.

KEYWORDS:

Aspartate aminotransferase/platelet ratio index (APRI); Chronic hepatitis C; Direct-acting antiviral agents; FIB-4; Liver stiffness measurement; Noninvasive fibrosis index; Platelet

PMID:
31029101
PMCID:
PMC6486982
DOI:
10.1186/s12876-019-0973-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center